Search

Your search keyword '"Park, Sung-Hwan"' showing total 2,124 results
Start Over Author "Park, Sung-Hwan"
2,124 results on '"Park, Sung-Hwan"'

11. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial

Author

Izumi, Keisuke, Kondo, Yasushi, Yoshimoto, Keiko, Gono, Takahisa, Park, Sung-Hwan, Baek, Han Joo, Lee, Yun Jong, Choi, In Ah, Kim, Jinhyun, Hsu, Ping-Ning, Huan, Chun-Ming, Weng, Meng-Yu, Sung, Wan-Yu, Cheng, Tien-Tsai, Tamai, Hiroya, Ikeda, Kei, Miyamoto, Toshiaki, Taguchi, Hiroaki, Kuo, Chang-Fu, Shin, Kichul, Hirata, Shintaro, Okano, Yutaka, Sato, Shinji, Yasuoka, Hidekata, Kuwana, Masataka, Ishii, Tomonori, Kameda, Hideto, Kojima, Toshihisa, Taninaga, Takehiro, Mori, Masahiko, Miyagishi, Hideaki, Sato, Yasunori, Tsai, Wen-Chan, Takeuchi, Tsutomu, and Kaneko, Yuko

Published
2023
Full Text
View/download PDF

25. Acupuncture for hot flashes in hormone receptor‐positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials.

Author

Lu, Weidong, Giobbie‐Hurder, Anita, Tanasijevic, Anna, Kassis, Sylvia Baedorf, Park, Sung Hwan, Jeong, Young Ju, Shin, Im Hee, Yao, Chang, Jung, Hyun Jung, Zhu, Zhiyuan, Bao, Chao, Bao, Ting, Yang, EunMee, Bierer, Barbara E., and Ligibel, Jennifer A.

Subjects
HOT flashes, PATIENT compliance, HORMONE therapy, ENDOCRINE glands, TREATMENT effectiveness, HORMONE receptor positive breast cancer
Abstract

Background: Hot flashes are a common side effect of endocrine therapy (ET) that contribute to poor quality of life and decreased treatment adherence. Methods: Patients with breast cancer wo were receiving ET and experiencing hot flashes were enrolled through three parallel, randomized trials conducted in the United States, China, and South Korea. Participants were randomized to either immediate acupuncture (IA) or delayed acupuncture control (DAC). IA participants received 20 acupuncture sessions over 10 weeks, whereas DAC participants received usual care, then crossed over to acupuncture with a reduced intensity. The primary end point was a change in score on the endocrine symptom subscale of the Functional Assessment of Cancer Therapy (FACT)‐Endocrine Symptoms between baseline and week 10. Secondary end points included the hot flash score and the FACT‐Breast score. A planned pooled analysis of individual patient data was performed using longitudinal mixed models. Results: In total, 158 women with stage 0–III breast cancer were randomized (United States, n = 78; China, n = 40; South Korea, n = 40). At week 10, IA participants reported statistically significant improvements in the endocrine symptom subscale score (mean change ± standard error: 5.1 ± 0.9 vs. 0.2 ± 1.0; p =.0003), the hot flash score (−5.3 ± 0.9 vs. −1.4 ± 0.9; p <.003), and the FACT‐Breast total score (8.0 ± 1.6 vs. −0.01 ± 1.6; p =.0005) compared with DAC participants. The effect of the acupuncture intervention differed by site (p =.005). Conclusions: Acupuncture led to statistically and clinically meaningful improvements in hot flashes, endocrine symptoms, and breast cancer‐specific quality of life in women undergoing ET for breast cancer in the United States, China, and South Korea. In a pooled analysis of three parallel trials, acupuncture significantly reduced hot flashes and other endocrine symptoms in women with stage 0–III breast cancer undergoing endocrine therapy in the United States, China, and South Korea. In the women studied, acupuncture led to statistically and clinically meaningful improvements in hot flashes, endocrine symptoms, and breast cancer‐specific quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

Author

Westhovens, Rene, Robles, Manuel, Ximenes, Antonio Carlos, Wollenhaupt, Jurgen, Durez, Patrick, Gomez-Reino, Juan, Grassi, Walter, Haraoui, Boulos, Shergy, William, Park, Sung-Hwan, Genant, Harry, Peterfy, Charles, Becker, Jean-Claude, and Murthy, Bindu

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Autoimmune Disease, Clinical Research, Arthritis, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Inflammatory and immune system, Abatacept, Adult, Antirheumatic Agents, Arthritis, Rheumatoid, Double-Blind Method, Female, Humans, Immunoconjugates, Induction Chemotherapy, Kaplan-Meier Estimate, Maintenance Chemotherapy, Male, Middle Aged, Prognosis, Recurrence, Remission Induction, Treatment Outcome, DMARDs, Disease Activity, Early Rheumatoid Arthritis, Rheumatoid Arthritis, Treatment, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo evaluate maintenance of response while reducing intravenous abatacept dose from ~10 mg/kg to ~5 mg/kg in patients with early rheumatoid arthritis (RA) who achieved disease activity score (DAS)28 (erythrocyte sedimentation rate, ESR)

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results